HEALTH
For decades the ritual has been the same, and every woman living with advanced breast cancer knows it by heart. You take the pills. You wait three months. You lie in the scanner. And then you wait for a radiologist somewhere to measure a shadow and tell you whether the drug that has been holding your life together has quietly stopped working.
By the time the scan speaks, the tumour has usually been shouting for months.
On Friday, the U.S. Food and Drug Administration did something it has never done before in cancer medicine. It approved a drug not on the evidence of a scan, but on the evidence of a blood test — a therapy triggered by a few floating fragments of tumour DNA, detected weeks or months before any image shows a thing.
The drug is camizestrant, sold as Etcamah, made by AstraZeneca. It is a once-daily tablet. And its approval, granted on 4 September 2026, has landed in the middle of one of the most bruising scientific arguments in modern oncology — because four months ago, the FDA’s own hand-picked panel of independent experts looked at exactly the same data and voted, 6 to 3, that it did not prove anything worth changing practice over.
The agency approved it regardless. Sort of.
What the drug actually does
To understand why this is a landmark and a lightning rod at the same time, you need to understand a single gene: ESR1.
Roughly two in three breast cancers are hormone receptor positive, meaning the tumour is fuelled by oestrogen. The standard opening move is to starve it — an aromatase inhibitor to shut down oestrogen production, paired with a CDK4/6 inhibitor such as palbociclib, ribociclib or abemaciclib to jam the cell’s division machinery. For many women that combination works beautifully, sometimes for years.
Then the tumour cheats.
Under the pressure of oestrogen starvation, cancer cells acquire mutations in ESR1 — the gene encoding the oestrogen receptor itself. The mutated receptor no longer needs oestrogen. It switches itself on. The aromatase inhibitor, still dutifully doing its job, becomes irrelevant overnight.
The FDA’s own numbers tell the story of how common this escape route is. At the point a woman is first diagnosed with hormone receptor positive metastatic breast cancer, fewer than 5 per cent carry an ESR1 mutation. After her disease progresses on an aromatase inhibitor, nearly 40 per cent do.
Camizestrant belongs to a class called oral selective oestrogen receptor degraders — SERDs. Rather than trying to cut off the fuel, it drags the receptor itself to the cellular shredder, mutated or not. It works where the older drugs have stopped working.
The revolutionary part is not the pill. It is the trigger
The trial that broke the rules
The study behind the approval is called SERENA-6, and it was built to answer a question nobody had ever formally tested: if you can see resistance coming in the blood, should you act on it, or should you wait for the scan?
The trial enrolled women already doing well on an aromatase inhibitor plus a CDK4/6 inhibitor. Their scans were clean. They felt fine. But alongside every routine imaging appointment, researchers drew blood and hunted for circulating tumour DNA — ctDNA, the microscopic debris that dying cancer cells shed into the bloodstream.
The moment an ESR1 mutation surfaced in that blood, and while the scans still showed nothing, patients were randomly assigned to one of two arms. Half switched to camizestrant at 75 milligrams a day, keeping the same CDK4/6 inhibitor. Half carried on exactly as before. Neither the women nor their doctors knew which group they were in.
The results, first unveiled at the American Society of Clinical Oncology meeting in 2025 and updated at the San Antonio Breast Cancer Symposium later that year, were emphatic on their own terms. Median progression-free survival — the time before the disease measurably worsened — was 16.0 months in the camizestrant group against 9.2 months for those who stayed the course, a 56 per cent reduction in the risk of progression or death. The updated San Antonio analysis put it at 16.6 months versus 9.2. By the third data cutoff, with a median of 23.5 months of follow-up, the figure had stretched to 16.8 months against 9.2.
The FDA’s approval notice cites an estimated median of 16 months against 9.2 months. Whichever cut you take, the pattern is the same: switching early roughly doubled the time before the cancer visibly advanced.
“Since I was in training, patients have wanted an actionable blood marker to inform whether a treatment is working. With ESR1 mutations, we finally have a marker, and with camizestrant, a way to effectively target it.” — Dr Kevin Kalinsky, Emory University School of Medicine
And then the panel said no
On 30 April 2026, the FDA convened its Oncologic Drugs Advisory Committee — ODAC, the independent body of outside specialists the agency turns to when a decision is genuinely difficult. AstraZeneca presented. Clinicians testified. And the committee voted 6 to 3 that the SERENA-6 data did not demonstrate a clinically meaningful benefit for switching treatment on a blood signal ahead of radiographic progression.
The objection was not that the drug does nothing. Everyone agreed it does something. The objection was subtler and, to the panel, more serious.
Progression-free survival was measured from the moment the mutation appeared in the blood — a starting line that only exists in the experimental arm’s logic. Nobody had shown that switching then is actually better than switching a few months later, when the scan finally catches up. And the measure that would have settled it — overall survival, the plain question of whether women live longer — remained immature.
Dr Stanley Lipkowitz of the National Cancer Institute explained his no vote in words that have been quoted across oncology ever since. "The data for changing the paradigm just isn’t there," he said. "There is a progression-free survival benefit — if there was an overall survival benefit, I think I would have voted yes, for sure. Aside from OS, I don’t see how they can demonstrate early versus late treatment at this point."
He added a warning about precedent: "I agree that the bar should be high here, because it’s changing fundamentally the way we do business, and I do agree with the FDA’s concern that all the subsequent trials will do exactly this, with no evidence that early treatment switch is improving outcomes."
Lipkowitz was careful to separate the drug from the strategy. "I want to make it clear, I’m excited about oral selective oestrogen receptor degraders," he said. "They’re going to change the field... But I couldn’t bring myself to say that we should fundamentally change the way we approach patients based on this data."
The FDA’s own clinical reviewer, Dr Joshua Donaldson, framed the agency’s discomfort carefully during the meeting. "We support innovative trial design strategies and deeply appreciate the patients and caregivers who participate in trials like SERENA-6," he said. "However, our responsibility is to determine whether the trial evidence demonstrates clinical benefit for the intended patient population, according to regulatory standards."
The compromise nobody quite expected
ODAC votes are advisory. The FDA is free to ignore them, and occasionally does. What happened next was more interesting than a straight override.
In May the agency pushed back its decision date to review supplementary analyses AstraZeneca had submitted on ctDNA clearance — evidence that the camizestrant combination was not merely delaying scans but scrubbing measurable tumour DNA out of patients’ blood entirely. Meanwhile, Europe moved first. The European Commission granted Etcamah marketing authorisation on 20 July 2026, and Japan had cleared it a month earlier, on 19 June, as Etokama.
When the American verdict finally came on Friday, it was not the full approval AstraZeneca had originally sought. It was an accelerated approval — the conditional pathway reserved for serious diseases with unmet need, granted on a surrogate endpoint, with confirmatory studies mandatory.
In other words: the FDA let the drug through the door while explicitly writing down that it is not yet convinced.
Dr Angelo de Claro, director of the FDA’s Oncology Center of Excellence, put both halves of that sentence in the same breath. "This marks the first FDA approval of a cancer therapy guided by the detection of a resistance mutation in circulating tumour DNA before imaging tests show that the disease is progressing," he said. "But additional evidence is needed to confirm clinical benefit."
Acting FDA Commissioner Kyle Diamantas was less hedged. "Women living with metastatic breast cancer face an uphill battle as their tumours continuously evolve to escape treatment. We owe them every weapon in our arsenal," he said. "Today’s approval delivers a win to these patients by granting them a targeted therapy designed specifically to overcome resistance, giving them more time before their disease progresses."
The blood test that comes with it
An approval built on a blood signal needs a blood test the FDA trusts. Alongside the drug, the agency authorised the Guardant360 CDx assay as the companion diagnostic — the officially sanctioned way to find the ESR1 mutation that unlocks the prescription.
That detail matters more than it sounds. It means the approval is not just a new pill on the shelf; it is a new clinical routine. Women on first-line hormone therapy will now have a reason to give blood at every scan appointment, and a specific, approved thing to do the moment the result comes back positive.
It also quietly turns liquid biopsy from a research tool into a billable, guideline-relevant standard of care in one of the most common cancers on earth.
The fine print: what it costs your heart
Camizestrant is not a gentle drug, and the label says so plainly. Etcamah carries a boxed warning — the FDA’s strongest — for the risk of irregular heart rhythm when taken alongside certain other medications. There are additional warnings for abnormally slow heart rate and for potential harm to an unborn baby.
The trial safety data give a fuller texture. Neutropenia, a drop in infection-fighting white cells, occurred in 32 per cent of the camizestrant group against 25 per cent of controls, with decreased neutrophil counts in 28 per cent versus 21 per cent. Anaemia hit 21 per cent in both arms. Two side effects stood out as distinctly camizestrant’s own: photopsia — flashes and flickers in the visual field — in 21 per cent versus 8 per cent, and dry eye in 12 per cent versus 7 per cent.
Cardiac effects drew particular attention at the advisory meeting, especially in combination with ribociclib, which carries its own rhythm risks.
What this means for you
If you or someone you love is living with hormone receptor positive, HER2-negative advanced breast cancer, the practical questions are short and worth asking out loud at the next appointment.
First: am I being monitored for ESR1 mutations with a blood test, or only with scans? Under this approval, that monitoring is now the gateway to a treatment option that did not formally exist a week ago.
Second: if a mutation is found, what does my oncologist think about switching immediately versus waiting? This is genuinely unsettled. Reasonable, well-informed specialists disagreed 6 to 3 in a public meeting. A doctor who wants to discuss the trade-off rather than reach straight for the prescription pad is not being obstructive; they are reading the same evidence the FDA read.
Third: what does it do to my heart, and what else am I taking? The boxed warning is about drug interactions. Bring the full list, including anything over the counter.
And fourth, unavoidably: what will it cost me? AstraZeneca has not publicly disclosed a U.S. price. In Britain, the cost-effectiveness watchdog NICE has already flagged the drug’s price as "higher than the range normally considered acceptable" — a phrase that tends to precede a fight.
The bigger argument
Strip away the acronyms and this approval is about a philosophical question that will define the next decade of cancer care: when a blood test can see the future, are you obliged to act on it?
Professor Nick Turner of the Institute of Cancer Research in London, co-principal investigator on SERENA-6, has made the patient-facing case for acting. Following the drug’s British clearance, he said the approval "is excellent news for patients, as they can stay on first line treatment and delay the need for chemotherapy for as long as possible."
That is not a trivial benefit. For a woman with metastatic disease, the months before chemotherapy are frequently the good months — the ones with hair, with energy, with normal life.
But the panel’s counter-argument has teeth too. Every drug company in oncology now has a template: find a resistance mutation, catch it early in the blood, run a trial with a starting line of your own choosing, show a progression-free survival gap, and file. If that template works without ever having to prove that patients live longer, the entire evidence bar for cancer approvals shifts — quietly, permanently, and in the industry’s favour.
The FDA has, in effect, split the difference. It let the first one through and demanded proof afterwards.
Confirmatory studies are now mandatory. If they show women actually live longer, camizestrant becomes the opening chapter of precision oncology’s next era, and the sceptics on ODAC will be remembered as cautious. If they do not, an accelerated approval can be withdrawn — and this one will be remembered as the moment the bar moved before anyone proved it should.
For the tens of thousands of women whose scans are clean today and whose blood is already whispering otherwise, that argument is not academic. It is the difference between waiting and acting. As of Friday, in America, acting is finally an option.
